Welcome to our dedicated page for PAVmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PAVmed Inc. SEC filings document its medical technology business, subsidiary operations and capital structure. Form 8-K reports cover operating results, business updates, Regulation FD disclosures, material agreements and Nasdaq listing-compliance matters for the company and its medical device, diagnostics and digital health activities.
Proxy statements and stockholder-meeting filings describe governance, voting matters and authorization of share issuances tied to preferred stock, warrants and convertible debt. Recent capital-structure disclosures include Series D Convertible Preferred Stock, warrants to purchase preferred stock, redemption of Series C Preferred Stock, and refinancing of a senior secured convertible note.
PAVmed Inc. (PAVM) entered into a Sales Agreement with A.G.P./Alliance Global Partners to establish an “at the market offering” program for its common stock. Under this arrangement, PAVmed may offer and sell, from time to time through or to the agent, up to $9,400,000 of common shares pursuant to its existing shelf registration statement on Form S-3.
The company will pay the agent a 3.0% commission on aggregate gross sales of shares and reimburse specified legal fees, including up to $65,000 at execution, quarterly amounts thereafter, and additional fees for program refreshes. Either party may terminate the agreement with ten business days’ written notice, and PAVmed states that net proceeds are intended for working capital and general corporate purposes.
PAVmed Inc. (PAVM) is establishing a new at-the-market equity program, allowing it to sell up to $9.4 million of common stock from time to time through or to A.G.P./Alliance Global Partners as sales agent or principal. A.G.P. will receive a 3.0% commission on the gross sales price of shares sold.
The company intends to use any net proceeds for working capital and general corporate purposes. As an illustration, if 1,846,758 shares are sold at $5.09 per share (the September 3, 2026 Nasdaq closing price), net tangible book value per share would rise to $3.54 while new investors would face about $1.55 of immediate dilution per share.
PAVmed highlights a history of operating losses, substantial doubt about its ability to continue as a going concern, challenges raising capital, significant outstanding convertible and equity-linked securities, and the possibility of additional future financings that could further dilute existing shareholders and pressure the share price.
PAVmed Inc. reported second-quarter 2026 results and a business update across its Lucid Diagnostics, Veris Health, and Octeris subsidiaries. Veris increased patient onboarding at OSU-The James and advanced development of its implantable physiological monitor toward an early 2027 FDA 510(k) submission, with design freeze nearing completion and successful manufacturing test runs. Lucid recognized $1.5 million in EsoGuard Esophageal DNA Test revenue in 2Q26 on 2,770 processed tests and secured its first laboratory benefit manager coverage policy for EsoGuard, already adopted by multiple health plans.
PAVmed’s revenue for the quarter ended June 30, 2026 was $33 thousand, compared with $6 thousand a year earlier. Total operating expenses were $7.1 million versus $4.7 million in 2Q25. Net loss as reported attributable to common stockholders was $5.4 million, with diluted loss per share of $0.87. EBITDA was a loss of $5.6 million, and non-GAAP adjusted loss was $1.7 million, or $0.27 per basic and diluted share.
PortIO first-in-human results were published, showing 100% device patency, 90% completion of intended implant duration, and no device-related adverse events, while Octeris advanced its multimodal endoscopic imaging probe toward clinical validation.
PAVmed Inc. received an updated ownership report from David S. Nagelberg and the David S. Nagelberg 2003 Revocable Trust. As of August 13, 2026, the Trust beneficially owns 474,542 shares of PAVmed common stock, representing 5.9% of the outstanding shares.
Including additional shares held outside the Trust, Mr. Nagelberg beneficially owns 699,778 shares in total, or 8.8% of the company’s 7,995,918 shares outstanding as of that date. Both the Trust and Mr. Nagelberg report sole voting and dispositive power over their respective holdings, with no shared power.
PAVmed Inc. reported minimal revenue and continued losses for the six months ended June 30, 2026 while relying heavily on financing transactions. Revenue was only $55,000 for the period, against operating expenses of $15.1 million, leading to an operating loss of $15.1 million and a net loss attributable to common stockholders of $12.5 million. Operating cash outflow was $5.3 million, leaving cash of $3.8 million and total assets of $40.2 million, most of which is the $33.5 million equity-method stake in Lucid Diagnostics.
The company completed a $30 million Series D preferred financing in February 2026, all of which converted into 4,615,393 common shares after shareholder approval, and issued a new $15.0 million Senior Secured Convertible Note due 2029 with a 15.0% coupon and tight covenants, including minimum cash and Lucid value tests. Legacy Series C preferred stock and the prior September 2022 note were redeemed or refinanced, generating a $3.4 million debt extinguishment loss and a $6.7 million deemed dividend. Management explicitly states that recurring losses, limited cash, small working capital of about $0.8 million, and dependence on raising additional capital and growing Veris revenue raise substantial doubt about PAVmed’s ability to continue as a going concern within one year of the report date.
PAVmed Inc. reported results of its annual stockholder meeting. Stockholders representing approximately 59.6% of shares outstanding and entitled to vote participated in person or by proxy. Management’s nominees Ronald M. Sparks and Timothy Baxter were re-elected as Class A directors.
Stockholders approved amendments to the Employee Stock Purchase Plan, increasing the total shares available from 15,774 to 215,774 and raising the annual limit on automatic share increases from 5,556 to 500,000. They also ratified CBIZ CPAs P.C. as the independent registered certified public accounting firm for the year ending December 31, 2026.
PAVmed Inc. ownership disclosure: Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 657,219 shares of Common Stock, representing 9.99% of the class as of March 31, 2026. The reported total includes 461,539 shares held by Two Seas Global (Master) Fund LP and 195,680 shares issuable upon exercise of warrants within 60 days, calculated against 6,383,089 shares outstanding on that date.
The filing states that Two Seas Capital has sole voting and dispositive power over the shares and warrants through its advisory and GP roles, and that the percentage figures give effect to a beneficial ownership limitation. Signatures indicate the statement was filed on behalf of the three reporting persons.
PAVmed Inc. reported first quarter 2026 results and a broad business update across its medical device, diagnostics, and digital health businesses. Revenue was $22 thousand, while operating expenses were about $8.1 million, leading to a GAAP net loss attributable to common stockholders of roughly $7.0 million, or $(4.42) per diluted share.
On a non-GAAP basis, PAVmed reported an adjusted loss of about $1.9 million, or $(1.17) per share. Cash and cash equivalents were $6.5 million as of March 31, 2026, up from $1.5 million at year-end 2025. Subsidiary Lucid Diagnostics recognized $1.3 million in EsoGuard test revenue, processed 3,177 tests, raised approximately $17 million through an underwritten offering, and ended the quarter with $45 million in pro forma cash, extending its runway into 2027.
Management highlighted Veris Health’s progress toward an FDA 510(k) submission for its implantable physiological monitor and deeper commercial engagement with The Ohio State University’s James Cancer Hospital. PAVmed also emphasized its simplified capital structure, strengthened balance sheet, and the advancement of its relaunched medical device portfolio, including the PortIO vascular access device and endoscopic esophageal imaging technology.
PAVmed Inc. reported first-quarter 2026 results showing minimal revenue and ongoing losses while relying heavily on financing transactions. Revenue for the three months ended March 31, 2026 was $22,000, against operating expenses of $8.1 million, leading to an operating loss of $8.0 million. After fair value gains on investments and debt and a large deemed dividend on preferred stock, net loss attributable to common stockholders was about $7.0 million, or $(4.42) per basic and diluted share.
To strengthen liquidity, PAVmed issued $30 million of Series D Convertible Preferred Stock and a new $15.0 million senior secured convertible note, refinanced prior convertible debt, redeemed its Series C preferred stock, and converted the Series D into 4,615,393 common shares. Cash increased to $6.5 million at March 31, 2026 from $1.5 million at year-end, and working capital was approximately $3.8 million. However, management disclosed that recurring losses, low revenues and dependence on additional capital raise substantial doubt about the company’s ability to continue as a going concern over the next year.
PAVmed Inc. ownership disclosure: First Manhattan Co. LLC, FMC Group Holdings LP and First Manhattan Management LLC report beneficial ownership of 639,191 shares of Common Stock, representing 9.6% of the class as of 03/31/2026. The cover page shows sole voting power 638,720 and shared voting power 471 for each filer.